BioCentury
ARTICLE | Clinical News

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

June 15, 2018 8:14 PM UTC

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of not impairing driving performance vs. placebo. Driving performance impairment was measured by mean changes in standard deviation of lateral position, an index of weaving, during an on-road driving test in the morning starting about nine hours post-dose. The active control zopiclone significantly impaired driving performance vs. placebo. Data were presented at the Associated Professional Sleep Societies meeting in Baltimore.

The double-blind, crossover, Dutch trial enrolled 48 healthy volunteers...